Gilbert syndrome and ischemic heart disease:: a protective effect of elevated bilirubin levels

被引:336
作者
Vítek, L
Jirsa, M
Brodanová, M
Kaláb, M
Marecek, Z
Danzig, V
Novotny, L
Kotal, P
机构
[1] Charles Univ Prague, Fac Med 1, Dept Internal Med 4, Prague 12808, Czech Republic
[2] Charles Univ Prague, Fac Med 1, Dept Internal Med 1, Prague 12808, Czech Republic
[3] Charles Univ Prague, Fac Med 1, Dept Internal Med 3, Prague 12808, Czech Republic
[4] Charles Univ Prague, Fac Med 1, Inst Clin Biochem, Prague 12808, Czech Republic
关键词
bilirubin; Gilbert syndrome; oxidation; ischemic heart disease;
D O I
10.1016/S0021-9150(01)00601-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Oxidation processes play an important role in atherogenesis. Bilirubin IXalpha is recognised as a potent antioxidant. In the present study, we assessed the role of elevated serum bilirubin levels in the prevention of ischemic heart disease (IHD). Methods: The occurrence of IHD was determined in Gilbert syndrome (GS) patients above 40 years (n = 50). The diagnosis was based on past medical history and ECG criteria. The occurrence was related to that of the comparable general population (n = 2296). Serum biochemistry, including the total antioxidant status was evaluated in the GS subjects. IHD patients (n = 38) and control subjects (n = 38). Results: The prevalence of IHD in GS subjects (aged 49.7 +/- 9.0 years) was 2% (0.05-10.7%, 95% confidence interval), compared to 12.1% in a general population (P < 0.05). Bilirubin. total antioxidant capacity and high density lipoprotein (HDL) cholesterol were found to be significantly higher in GS subjects compared to control groups (P < 0.05). According to linear discriminant analysis, hyperbilirubinemia rather than elevation of HDL cholesterol levels seemed to be more important in protection from IHD. Conclusions: In the present study, low prevalence of IHD in GS subjects was detected. It may be presumed that chronic hyperbilirubinemia prevent the development of IHD by increasing the serum antioxidant capacity. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:449 / 456
页数:8
相关论文
共 52 条
[41]  
RICEEVANS C, 1994, METHOD ENZYMOL, V234, P279
[42]   THE PATHOGENESIS OF ATHEROSCLEROSIS - A PERSPECTIVE FOR THE 1990S [J].
ROSS, R .
NATURE, 1993, 362 (6423) :801-809
[43]   Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease [J].
Schwertner, HA ;
Fischer, JR .
ATHEROSCLEROSIS, 2000, 150 (02) :381-387
[44]  
SCHWERTNER HA, 1994, CLIN CHEM, V40, P18
[45]  
Sharma HS, 1996, MOL CELL BIOCHEM, V157, P111
[46]  
Sharma S C, 1985, J Assoc Physicians India, V33, P473
[47]   BILIRUBIN IS AN ANTIOXIDANT OF POSSIBLE PHYSIOLOGICAL IMPORTANCE [J].
STOCKER, R ;
YAMAMOTO, Y ;
MCDONAGH, AF ;
GLAZER, AN ;
AMES, BN .
SCIENCE, 1987, 235 (4792) :1043-1046
[48]  
TOGLLEIMULLER A, 1986, EXP PATHOL-JENA, V30, P91
[49]   ROLE OF ENDOTHELIAL-CELLS AND THEIR PRODUCTS IN THE MODIFICATION OF LOW-DENSITY LIPOPROTEINS [J].
VANHINSBERGH, VWM ;
SCHEFFER, M ;
HAVEKES, L ;
KEMPEN, HJM .
BIOCHIMICA ET BIOPHYSICA ACTA, 1986, 878 (01) :49-64
[50]   Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins [J].
Wu, TW ;
Fung, KP ;
Wu, J ;
Yang, CC ;
Weisel, RD .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (06) :859-862